Антипсихотик нового поколения карипразин (Реагила) в лечении шизофрении: спектр клинической эффективности и безопасности

Цель: по данным научных публикаций представить анализ свойств новейшего антипсихотика третьего поколения карипразина, частичного агониста дофаминовых рецепторов с уникальным предпочтительным взаимодействием с D3- относительно D2-рецепторов.

Материалы и метод: по ключевым словам «шизофрения», «негативные расстройства», «терапия», «карипразин» проведен поиск и анализ научных статей в базах данных MEDLINE, PubMed и в других библиографических источниках за период с 2000 по 2020 г.

Заключение: обобщены данные преклинических и клинических исследований препарата с последовательным анализом параметров фармакодинамики, фармакокинетики, клинической эффективности, переносимости и безопасности на всех этапах терапии шизофрении, включая купирующую терапию обострений и длительную поддерживающую терапию с профилактикой рецидивов. Сформулированы предварительные рекомендации по применению карипразина в клинической практике с учетом особенностей фармакологических и клинических характеристик препарата.

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–93. DOI: 10.1038/nature09552. PMID: 21068826

2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007;64(10):1123–31. DOI: 10.1001/archpsyc.64.10.1123 PMID: 17909124

3. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr. Dis. Treat. 2016;12:357–73. DOI: 10.2147/NDT.S96649 PMID:26937191;PMCID:PMC4762470

4. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr. Res. 2009;110(1–3):1–23. DOI: 10.1016/j.schres.2009.03.005 Epub 2009 Mar 27. PMID: 19328655

5. Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules. 2018;23(8):2087. DOI: 10.3390/molecules23082087 PMID: 30127324; PMCID: PMC6222385

6. Stroup TS, Lieberman JA, Swartz MS, McEvoy JP. Comparative effectiveness of antipsychotic drugs in schizophrenia. Dialogues Clin. Neurosci. 2000;2(4):373–9. PMID: 22033808; PMCID: PMC3181620

7. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am. J. Psychiatry. 2017;174(10):927–942. DOI: 10.1176/appi.ajp.2017.16121358 Epub 2017 May 25. PMID: 28541090

8. Huhn M, Nikolakopoulou A, Schneider–Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. DOI: 10.1016/S0140-6736(19)31135-3 Epub 2019 Jul 11. Erratum in: Lancet. 2019;394(10202):918 PMID: 31303314; PMCID: PMC6891890

9. Быков ЮВ, Беккер РА, Морозов ПВ. Эффективность карипразина в лечении шизофрении, особенно с преобладанием негативной симптоматики. Психиатрия и психофармакотерапия. 2018;5:27–37. Портал CON-MED.RU: http://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-05-2018/ef fekt ivnost_kariprazina_v_lechenii_shizofrenii_osobenno_s_preobladaniem_negativnoy_simptomatiki

10. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4rd Ed. 2013.

11. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther. Adv. Psychopharmacol. 2017;7(1):29–41. DOI: 10.1177/2045125316672136 Epub 2016 Oct 17. PMID:28101322; PMCID: PMC5228714.

12. Citrome L. The ABC’s of dopamine receptor partial agonists — aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int. J. Clin. Pract. 2015;69(11):1211–20. DOI: 10.1111/ijcp.12752 Epub 2015 Oct 18. PMID:26477545

13. ГРЛС pharm-portal. https://grls.pharm-portal.ru/grls/70311075-c0fe-42d6-af96-826453027a7f?-f i l ter s%5Bt r ade _name%5D%5B0%5D%5Bte x t%5D = р е а г и л а&f i l t e r s%5 B t r a d e _n a m e%5D%5B 0%5D %5B e x a c t %5D = 0& -search=реагила&sort%5Breg_date%5D=desc#summary

14. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 2010;333(1):328–40. DOI: 10.1124/jpet.109.160432 Epub 2010 Jan 21. PMID:20093397

15. Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr. Dis. Treat. 2019;15:2537–2550. DOI: 10.2147/NDT.S210340 PMID:31507322

16. Stahl SM. Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors. CNS Spectr. 2017;22(4):305–311. DOI: 10.1017/S1092852917000426 PMID:28758887

17. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr. Res. 2014;152(2–3):450–7. DOI: 10.1016/j.schres.2013.11.041 Epub 2014 Jan 10. PMID:24412468

18. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. J. Clin. Psychopharmacol. 2015;35(4):367–73. DOI: 10.1097/JCP.0000000000000346

19. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J. Clin. Psychiatry. 2015;76(12):1574–82. DOI: 10.4088/JCP.15m09997. PMID: 26717533

20. Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int. Clin. Psychopharmacol. 2016;31(2):61–8. DOI: 10.1097/YIC.0000000000000110 PMID: 26655732

21. Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int. Clin. Psychopharmacol. 2017;32(6):309–318. DOI: 10.1097/YIC.0000000000000189 PMID: 28727644

22. Zhao MJ, Qin B, Wang JB, Zhang YP, Zhao JT, Mao YG, Zhang XY, Zhang RL. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J. Clin. Psychopharmacol. 2018;38(1):55–59. DOI: 10.1097/JCP.0000000000000834 PMID: 29257786

23. Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J. Clin. Psychiatry. 2016;77(1):109–15. DOI: 10.4088/JCP.15m10192 PMID: 26845266

24. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr. Res. 2016;176(2–3):264–271. DOI: 10.1016/j.schres.2016.06.030 Epub 2016 Jul 15. Erratum in: Schizophr Res. 2018 Feb;192:493. PMID: 27427558

25. Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur. Neuropsychopharmacol. 2014;24(5):788–799. DOI: 10.1016/j.euroneuro. 2013.10.010

26. Bitter I. Managing Negative Symptoms of Schizophrenia. Oxford University Press, 2020.

27. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2018 Oct;268(7):625–639. DOI: 10.1007/s00406-018-0869-3 Epub 2018 Jan 24. PMID:29368205.

28. Мосолов СН, Ялтонская ПА. Алгоритм терапии первичной негативной симптоматики при шизофрении. Современная терапия психических расстройств. 2020;(2):2–10. DOI: 10.21265/PSYPH.2020.26.17.001

29. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitterz I, Marder S, Fleischhacker WW. Cariprazine versus risperidonemonotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113. DOI: 10.1016/S0140-6736(17)30060-0 Epub 2017 Feb 7. Erratum in: Lancet. 2017 Mar 18;389(10074):1102. PMID:28185672

30. Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur. Psychiatry. 2019;58:1–9. DOI: 10.1016/j.eurpsy.2019.01.015 Epub 2019 Feb 7. PMID: 30738380

31. Németh B, Molnár A, Akehurst R, Horváth M, Kóczián K, Németh G, Götze Á, Vokó Z. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J. Comp. Eff. Res. 2017;6(8):639–648. DOI: 10.2217/cer-2017-0024 Epub 2017 May 17. PMID:28511548

32. Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol. 2017;32(6):319–328. DOI: 10.1097/YIC.0000000000000187 PMID: 28692485; PMCID: PMC5625952

33. Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305. DOI: 10.1186/s12888–017–1459–z PMID: 28836957; PMCID: PMC5571492

34. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S. Safety and tolerabil ity of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017;234(2):199–209. DOI: 10.1007/s00213-016-4450-3 Epub 2016 Nov 2. PMID:27807604; PMCID: PMC5203812

35. Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39–50. DOI: 10.1017/S1092852917000220 Epub 2017 May 8. PMID: 28478771